# Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas

> **NCT03920631** · PHASE1 · WITHDRAWN · sponsor: **Ahmed Galal, MD**

## Conditions studied

- B Cell Lymphomas

## Interventions

- **DRUG:** Nivolumab
- **BIOLOGICAL:** Microtransplantation

## Key facts

- **NCT ID:** NCT03920631
- **Lead sponsor:** Ahmed Galal, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-10
- **Primary completion:** 2023-03-15
- **Final completion:** 2023-05-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03920631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03920631, "Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03920631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*